SAIPARENT Q4 FY26 earnings call.
A source-linked concall view: reported numbers, management language, guidance, commitments and risks that should carry forward.
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Revenue
₹197.93 Cr
verified against source
Revenue YoY
133%
reported change
EBITDA
₹47 Cr
latest reported figure
Source
screener in
record provenance
Actual signal trajectory
Where this quarter sits.
Quarter read
What the record says.
Sai Parenterals delivered a transformational FY26 with consolidated revenue of Rs 381 crore (133% YoY growth) following the November 2025 acquisition of Numed Pharmaceuticals. The Q4 standalone business showed strong momentum with 30% revenue growth to Rs 162 crore and 60% PAT growth to Rs 17 crore. Management guided for FY27 revenue of Rs 750 crore with 17% EBITDA margin, underpinned by long-term CDMO contracts (50%+ revenue from regulated markets), 67 dossiers under development, and the Adelaide facility commissioning by Q4 FY27. The Rs 440 crore capex program remains on track but will not contribute to FY27 earnings as facilities commission late in the year. FY28 is positioned as the inflection point when vertical integration (internalizing Numed's outsourced manufacturing), operating leverage, and IP monetization drive margin expansion. Key risks include Adelaide plant ramp-up execution, integration execution between entities, and AUD 40 million remaining capex deployment in Australia.
Colored figures show movement against the previous available record.
Guidance to track
- Management targets Rs 750 crore revenue for FY27 driven by execution of existing long-term contracts, new dossier commercialization, increasing Numed contribution, and momentum in CDMO export business. H2 expected to be heavier than H1.
- EBITDA margin guidance of 17% for FY27, up from ~12.3% in FY26, driven by vertical integration benefits as Numed manufacturing shifts to Sai's own facilities.
- None of the ongoing Rs 440 crore capex projects will contribute to FY27 financials as most facilities will be commissioned towards end of the year. Full impact expected in FY28.
- By FY28, majority of capex program expected operational including Adelaide facility, expanded Indian capacities, EU GMP infrastructure, and R&D center—all contributing to revenue and margin expansion.
Risks flagged
- TGA licensing expected by March 31 next year. Clean rooms, utilities, and equipment validation ongoing. Commissioning delays could impact FY28 vertical integration benefits.
- Numed derives significant revenue from two top 20 ASX customers—Westfarmers Health and EBOS Group. Loss of either relationship could materially impact Australian segment performance.
- Analyst raised concern: consolidated PBT decreased to Rs 18.85 crore from Rs 14.4 crore YoY despite revenue doubling. Management attributed to acquisition costs and integration expenses but did not provide detailed breakdown.
- Of the AUD 53 million total Adelaide investment, AUD 40 million has been invested. Balance capex needs to be deployed and commissioned by Q4 FY27, requiring continued cash deployment during peak debt period.
Key quotes
- FY27 will be a year of execution. We believe FY28 will be the year when the full impact of our investments begins to reflect in our financial performance.
- None of the ongoing capex projects with 440 crore capex program are expected to contribute to FY27 financial performance as most of the facilities will be commissioned towards the end of the year.
- We are targeting a revenue of 750 crore with an EBITDA margin of 17%.
Research modules